Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s share price was down 7.7% during trading on Thursday . The company traded as low as $0.23 and last traded at $0.24. Approximately 1,199,966 shares were traded during trading, a decline of 26% from the average daily volume of 1,625,809 shares. The stock had previously closed at $0.26.
The company has a quick ratio of 4.65, a current ratio of 5.24 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $20.96 million, a P/E ratio of -0.34 and a beta of 0.48.
Titan Pharmaceuticals (NASDAQ:TTNP) last posted its quarterly earnings results on Wednesday, November 14th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Titan Pharmaceuticals had a negative return on equity of 878.37% and a negative net margin of 168.73%. The business had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $0.10 million. Equities analysts expect that Titan Pharmaceuticals, Inc. will post -0.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by PressOracle and is the sole property of of PressOracle. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://pressoracle.com/news/2019/01/11/titan-pharmaceuticals-ttnp-trading-down-7-7.html.
About Titan Pharmaceuticals (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.